OOIR: Observatory of International Research

Papers

(The H4-Index of Blood Advances is 59. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.	226
Abramson JS, Siddiqi T, Garcia J, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6)	167
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study	166
Addressing and overcoming disparities in GVHD	154
Predictors of liver disease outcomes in individuals with hemophilia and HCV infection	130
On a collision course: SARS-CoV-2 variants and CAR T cells	127
Converting IMPROVE bleeding and VTE risk assessment models into a fast-and-frugal decision tree for optimal hospital VTE prophylaxis	127
Campbell BA, Dobos G, Haider Z, et al. International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies. Blood Adv. 2023;7(21):	125
Kennedy VE, Wong C, Huang C-Y, et al. Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. Blood Adv. 2021;5(23):5344-5348.	117
Pirillo C, Birch F, Tissot FS, et al. Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness. Blood Adv. 2022;6(10):3126-3141.	115
Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies	110
Complement C5 inhibition in early onset HELLP syndrome	107
Complete absence of GLUT1 does not impair human terminal erythroid differentiation	106
Pirfenidone for the treatment of bronchiolitis obliterans syndrome related to chronic graft-versus-host disease	102
COVID-19 vaccination during therapy in relation to COVID-19 death in CLL	100
Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi	98
Cortisol in sickle cell disease: a systematic review and meta-analysis	95
Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization	94
Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis	93
Diagnostic Criteria for NK-Cell Large Granular Lymphocyte Leukemia: Validation Through a Multicentric International Study	91
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea	87
Molecular subclusters of follicular lymphoma: a report from the United Kingdom’s Haematological Malignancy Research Network	84
Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia	84
Regional Brain Age is Decreased in Children with Sickle Cell Anemia	82
Targeting bone marrow mesenchymal stromal cell–derived IL-6 to overcome acute myeloid leukemia chemoresistance	81

Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination	81
Transfusion therapy for sickle cell disease: what’s new?	76
Best but not perfect: indirect measure of low iron stores	75
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis	75
Selective modulation of activated protein C activities by a nonactive site–targeting nanobody library	73
Deep PIM kinase substrate profiling reveals new rational cotherapeutic strategies for acute myeloid leukemia	73
Genome editing of patient-derived iPSCs identifies a deep intronic variant causing aberrant splicing in hemophilia A	71
The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool	71
Conditioning intensity and probability of live birth after blood or marrow transplantation, a BMTSS report	71
Clinical Trial Success Rate in Lymphoma: Fate of Trials and Agents from 2000 to 2019	70
Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia	70
Sickle cell disease is a risk factor for transplant-associated thrombotic microangiopathy in children	70
Bite-size introduction to canine hematologic malignancies	70
Priapism before and after hematopoietic stem cell therapy in individuals with sickle cell disease	70
The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma	69
Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial	67
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma	66
Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry	66
Steroid tapering after GVHD Rx: not too fast, not too slow	66
Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703	66
Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL	64
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML	63
A mouse model for hemoglobin SC disease recapitulates characteristic human pathologies	63
Structural analysis of platelet fragments and extracellular vesicles produced by apheresis platelets during storage	62
Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years	62
CAR T cells targeting C-C motif chemokine receptor 4 (CCR4) selectively deplete human Tregs ex vivo and in vivo	61
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma	60
ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV	60
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients	59
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia	59
International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies	59
Applying CRISPR-Cas9 screens to dissect hematological malignancies	59
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel	59
Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia	59